Kickboxing HIIT study reveals protein changes in elite athletes

NCT ID NCT07449663

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how sport-specific high-intensity interval training (HIIT) changes certain proteins in the blood of elite kickboxers. Forty male athletes aged 18 to 30 with at least five years of training will be randomly assigned to either an eight-week HIIT program or their usual training. The goal is to see if HIIT affects levels of apelin and irisin, which are linked to how the body adapts to exercise. The results could help coaches design better training programs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male elite kickboxers aged 18 to 30 years * At least five years of regular kickboxing training experience * Active participation in kickboxing training * Ability to complete the training program Exclusion Criteria: * Serious injury within the previous six months * Presence of chronic or cardiometabolic disease * Regular use of medications or ergogenic supplements * Tobacco or alcohol use * Inability to complete the training program

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Exercise physiology are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Adiyaman University Faculty of Sport Sciences

    Adıyaman, 02040, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.